<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-related <z:mpath ids='MPATH_3'>apoptosis</z:mpath>-inducing ligand (TRAIL, APO2L) has been shown to induce <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in a number of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell lines as well as in some <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> whereas cells from most <z:mpath ids='MPATH_458'>normal</z:mpath> tissues are highly resistant to TRAIL-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>We have studied the susceptibility of primary malignant and <z:mpath ids='MPATH_458'>normal</z:mpath> bone marrow hematopoietic progenitors to TRAIL-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>Extracellular domain of human TRAIL with N-terminal His(6) tag (His-TRAIL, amino acids 95-281) was produced in E. coli and its <z:mpath ids='MPATH_3'>apoptosis</z:mpath>-inducing ability was compared with the leucine-zipper containing TRAIL, LZ-TRAIL </plain></SENT>
<SENT sid="3" pm="."><plain>Both variants of TRAIL had the same <z:mpath ids='MPATH_3'>apoptosis</z:mpath>-inducing ability </plain></SENT>
<SENT sid="4" pm="."><plain>Clonogenic progenitor assays showed that His-TRAIL significantly reduced the number of myeloid colonies (CFU-GM) and clusters from patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>), and <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="5" pm="."><plain>His-TRAIL had no negative effect on the number of CFU-GM colonies and clusters derived from bone marrow cells of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients in complete remission, and <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients without bone marrow involvement, as well as those derived from <z:mpath ids='MPATH_458'>normal</z:mpath> cord blood cells </plain></SENT>
<SENT sid="6" pm="."><plain>Moreover, we found that <z:mpath ids='MPATH_458'>normal</z:mpath> human stem cells treated with high doses of His-TRAIL maintain a repopulating potential when transplanted into <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NOD</z:e>/<z:mp ids='MP_0002536'>SCID</z:mp> mice </plain></SENT>
<SENT sid="7" pm="."><plain>To conclude, our data document that TRAIL does not affect <z:mpath ids='MPATH_458'>normal</z:mpath> human hematopoiesis but suppresses the growth of early primary <z:hpo ids='HP_0001909'>leukemia</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> progenitors </plain></SENT>
</text></document>